Malaria Vaccines Market, By Vaccines Type (Pre-Erythrocytic Vaccine, Erythrocytic Vaccine, Multi-antigen Vaccine), Agent (Plasmodium Falciparum, Plasmodium Vivax), Distribution Channel (Hospitals, Clinics, Community Centers), and Geography - Insights, Opp

Malaria Vaccines Market, By Vaccines Type (Pre-Erythrocytic Vaccine, Erythrocytic Vaccine, Multi-antigen Vaccine), Agent (Plasmodium Falciparum, Plasmodium Vivax), Distribution Channel (Hospitals, Clinics, Community Centers), and Geography - Insights, Opportunity Analysis, and Industry Forecast, 2024 - 2027

Malaria is a severe and widespread disease caused by a parasitic infection by protozoan Plasmodium when transmitted by various species of anopheles mosquitoes. In 2009, according to WHO, 214 Mn to 397 Mn clinical malaria cases were reported worldwide. However, high estimates of around 515 Mn clinical cases of P. falciparum were projected in 2002. Furthermore, malaria accounted for around 3% of the world’s total Disability Adjusted Life Years (DALYs) lost and around 10% in Africa alone. According to Centers for Disease Control and Prevention (CDC), there are around 156 types of Plasmodium species that infect various species of vertebrates. Among the numerous plasmodium species, four are considered true parasites of humans, as they utilize humans almost exclusively as a natural intermediate host: P. falciparum, P. vivax, P. ovale and P. malariae. Over 85% of malaria mortality is due to P. falciparum. Around 90% of deaths caused by malaria in Sub-Saharan Africa is primarily due to P. falciparum.

Market Dynamics

The growing incidence of malaria globally and major players pledging for low profit margin over vaccines is expected to boost growth of the malaria vaccines market. According to World Health Organization (WHO), in 2015, approximately 292,000 children in Africa died of malaria, at very early age of 5 years. Around 306,000 fatalities associated with malaria were reported worldwide in 2015, out of which around 90% cases were reported in Africa.

According to World Health Organization (WHO), first global malaria vaccines has been piloted in the 3 countries of sub-Saharan Africa in April 2019, with the total investment of around US$ 1 Bn. The program is partly funded by the Bill & Melinda Gates Foundation and African Research Centers. The vaccine is being developed by GSK at their lab in Belgium in collaboration with Path, which is an international non-profit organization. This ensures the cost effectiveness of the vaccine though it has taken around 30 years to develop at a cost of US$ 565 Mn. The company pledges not to make a profit from sales of the vaccine and adheres to the price range of around US$ 5 per shot.

Key features of the study:

This report provides in-depth analysis of the malaria vaccines and is its use, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period (2022 - 2028), considering 2021 as the base year.
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global malaria vaccines market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, Distribution Channel strategies, key developments and strategies and future plans
Key companies covered as a part of this study include GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Ltd., Sumaya Biotech and GenVec Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics
The global malaria vaccines market report caters to various stakeholders in this industry, including investors, drug/product manufacturers, distributors and suppliers for malaria vaccines market, research and consulting firms, new entrants, and financial analysts
Various strategy matrices used in analyzing the malaria vaccines market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:

Global Malaria Vaccines Market, By Vaccines Type:
Pre-Erythrocytic Vaccine
Erythrocytic Vaccine
Multi-antigen Vaccine
Global Malaria Vaccines Market, By Agent:
Plasmodium Falciparum
Plasmodium Vivax
Global Malaria Vaccines Market, By Distribution Channel:
Hospitals
Clinics
Community Centers
Global Malaria Vaccines Market, By Geography:
North America
By Vaccines Type:
Pre-Erythrocytic Vaccine
Erythrocytic Vaccine
Multi-antigen Vaccine
By Agent:
Plasmodium Falciparum
Plasmodium Vivax
By Distribution Channel:
Hospitals
Clinics
Community Centers
By Country:
U.S.
Canada
Europe
By Vaccines Type:
Pre-Erythrocytic Vaccine
Erythrocytic Vaccine
Multi-antigen Vaccine
By Agent:
Plasmodium Falciparum
Plasmodium Vivax
By Distribution Channel:
Hospitals
Clinics
Community Centers
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia-Pacific
By Vaccines Type:
Pre-Erythrocytic Vaccine
Erythrocytic Vaccine
Multi-antigen Vaccine
By Agent:
Plasmodium Falciparum
Plasmodium Vivax
By Distribution Channel:
Hospitals
Clinics
Community Centers
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Vaccines Type:
Pre-Erythrocytic Vaccine
Erythrocytic Vaccine
Multi-antigen Vaccine
By Agent:
Plasmodium Falciparum
Plasmodium Vivax
By Distribution Channel:
Hospitals
Clinics
Community Centers
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
By Vaccines Type:
Pre-Erythrocytic Vaccine
Erythrocytic Vaccine
Multi-antigen Vaccine
By Agent:
Plasmodium Falciparum
Plasmodium Vivax
By Distribution Channel:
Hospitals
Clinics
Community Centers
By Country:
GCC
Israel
Rest of Middle East
Africa
By Vaccines Type:
Pre-Erythrocytic Vaccine
Erythrocytic Vaccine
Multi-antigen Vaccine
By Agent:
Plasmodium Falciparum
Plasmodium Vivax
By Distribution Channel:
Hospitals
Clinics
Community Centers
By Country:
North Africa
Central Africa
South Africa
Company Profiles
GlaxoSmithKline plc *
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Future Plans
Sanaria Inc.
Nobelpharma Co., Ltd.
Sumaya Biotech
GenVec, Inc.
“*” marked represents similar segmentation in other categories in the respective section.